Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Library: SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

Official URL: https://fevir.net/resources/Library/179632 Version: 1.0.0-ballot2
Standards status: Informative Computable Name:
Other Identifiers: FEvIR Object Identifier: 179632, OID:2.16.840.1.113883.4.642.40.44.28.2

Usage:Evidence Communication: SystematicReviewExcludedStudies

Copyright/Legal: https://creativecommons.org/licenses/by-nc-sa/4.0/

11 excluded studies

Title: SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
Id: 179632
Version: 1.0.0-ballot2
Url: SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
Accession ID (Computable Publishing LLC) Identifier:

179632

urn:oid:2.16.840.1.113883.4.642.40.44.28.2

Type:

system: http://terminology.hl7.org/CodeSystem/library-type

code: asset-collection

display: Asset Collection

Subject:

reference: Group/179619

type: http://hl7.org/fhir/StructureDefinition/Group

code: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

Date: 2023-11-26 18:15:27+0000
Publisher: HL7 International / Clinical Decision Support
Description:

11 excluded studies
Use Context:
code value
evidence-communication
Jurisdiction: 001
Copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/
Related Artifacts:

Derived From